Abbvie, ticker symbol $ABBV, has managed to weather the storm of life after Humira much better than many thought. That is because of its cash flows, its pipeline, as well as its shareholder-friendly activities. Not exactly exciting, but boring is good in many cases. Want to know what I think of ABBV? Is it a healthcare holding staple, or one that’s appreciated by you only during volatile market conditions?